{"url_path":"/sec/ptct/8-k/2026-06-16/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 ****Financial Statements and Exhibits.  **","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-16","source_url":"https://www.sec.gov/Archives/edgar/data/1070081/0001104659-26-074292-index.html","accession_number":"0001104659-26-074292","cik":"0001070081","ticker":"PTCT","issuer_name":"PTC THERAPEUTICS, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1070081/0001104659-26-074292-index.html","primary_entity_key":"0001070081","primary_entity_name":"PTC THERAPEUTICS, INC."},"word_count":360,"has_tables":true,"body_markdown":"**Item 9.01.****Financial Statements and Exhibits.  **\n\n \n\n (d) Exhibits.\n\n \n\nExhibit No.\n \nDescription\n\n[99.1](tm2618041d1_ex99-1.htm)\n \n[Press Release of PTC Therapeutics,\nInc. dated June 15, 2026.](tm2618041d1_ex99-1.htm)\n\n104\n \nThe cover page from this Current\nReport on Form 8-K, formatted in Inline XBRL\n\n \n\n \n\n \n\n \n\n**Cautionary Note Regarding Forward-Looking Statements**\n\n** **\n\nThis Current Report on Form 8-K contains information about future\nexpectations, plans and prospects of the Company’s management that constitute forward-looking statements for purposes of the safe\nharbor provisions under The Private Securities Litigation Reform Act of 1995, including statements with respect to the Company’s\nexpectations to complete the Offering, its use of proceeds from the Offering and the effect of the concurrent note repurchase. There\ncan be no assurance that the Company will be able to complete the Offering on the anticipated terms, or at all. Actual results may differ\nmaterially from those indicated by these forward-looking statements as a result of various important factors including, but not limited\nto, the terms of the Notes and the Offering, risks and uncertainties related to whether or not the Company will consummate the Offering,\nthe impact of general economic, industry, market or political conditions and other factors that are discussed in the Company’s\nAnnual Report on Form 10-K, Quarterly Reports on Form 10-Q, and other documents periodically filed with the Securities and Exchange Commission.\n\n \n\nIn addition, the statements in this Current Report on Form 8-K represent\nthe Company’s expectations and beliefs as of the date of this Current Report on Form 8-K. The Company anticipates that subsequent\nevents and developments may cause these expectations and beliefs to change. However, while the Company may elect to update these forward-looking\nstatements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not\nbe relied upon as representing the Company’s expectations or beliefs as of any date subsequent to the date of this Current Report\non Form 8-K.\n\n \n\n \n\n \n\n \n\n**SIGNATURE**\n\n \n\nPursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf\nby the undersigned hereunto duly authorized.\n\n \n\n \n**PTC Therapeutics, Inc.**\n\n \n \n\nDate: June 16, 2026\nBy:\n/s/\nPierre Gravier\n\n \n \nPierre Gravier\n\n \n \nChief Financial Officer"}